Pravastatin prevents glomerular injury in FB1-, FC1-, and aPL-IgG–treated mice. (A) BUN levels. Mice treated with pravastatin exhibited a significant decrease in BUN levels compared with FB1-, FC1-, and aPL-IgG–treated mice, respectively. *P < .005. (B) Urinary ACR. Pravastatin treatment prevented the development of albuminuria in FB1-, FC1-, and aPL-IgG–treated mice. *P < .005. (C) TAT complex levels. FB1-, FC1-, and aPL-IgG–treated mice that received pravastatin treatment showed decreased TAT levels compared with mice did not receive pravastatin. *P < .001. Pravastatin diminished TAT values in FB1-treated mice. *Different from mIgG-treated mice (P < .001). (D) Transmission electron micrograph of glomeruli. Patent capillary lumina, thin endothelium with abundant and well-preserved fenestrations (—) is observed in FB1- (i), FC1- (ii), and aPL-IgG–treated mice (iii) that received pravastatin treatment. (E) Glomerular injury scores. Pravastatin treatment diminished glomerular injury scores in FB1-, FC1-, and aPL-IgG–treated mice. *P < .01.